EasyDiagnosis

Wuhan EasyDiagnosis Biomedicine Co., Ltd. is a national high-tech enterprise that professionally provides in vitro diagnostic reagents and supporting instruments (POCT/molecular diagnostics/chemiluminescence/blood gas analysis, etc.) products as well as integrated emergency and critical care treatment solutions (chest pain centers/stroke centers/trauma centers), PCR laboratory construction, and intelligent fever clinic development services. It is recognized as the Hubei Provincial Enterprise Technology Center and Wuhan Municipal Enterprise Research and Development Center. During the fight against the COVID-19 pandemic, EasyDiagnosis urgently developed a nucleic acid detection kit for the novel coronavirus and obtained registration certification, becoming a representative IVD company in the epidemic area. Meanwhile, EasyDiagnosis's nucleic acid test kits, antibody test kits, and blood gas analyzers received EU CE certification, gaining eligibility for overseas sales. EasyDiagnosis has successively passed the EU CE certification and ISO13485 quality management system certification, with over 30 POCT rapid diagnostic reagent products registered with the CFDA. The company has achieved rapid point-of-care testing for PCT procalcitonin and S100-β protein in whole blood. Its product portfolio covers multiple fields including cardiovascular and cerebrovascular diseases, infectious diseases, kidney diseases, diabetes, health check-ups, and obstetrics and gynecology, making it one of the domestic companies with a relatively rich POCT product line. EasyDiagnosis’s self-developed immunological quantitative detection platform enables one-step operation, intelligent recognition, and quick acquisition of test results within 15 minutes, while being compatible with nearly 30 immunological markers. This platform is suitable not only for rapid diagnosis of bedside emergencies in large and medium-sized hospitals but also for immunological quantitative analysis in the laboratories of small and medium-sized hospitals, and meets the needs of primary hospitals for instant testing of common diseases. Currently, more than 5,000 medical institutions across China use EasyDiagnosis’s POCT products, with secondary-level hospitals and above accounting for over 60%. Since 2017, EasyDiagnosis has successively launched its immunological quantitative analyzer, dry fluorescence immunological quantitative analyzer, 12-lead mobile electrocardiograph (remote ECG network construction), HB1000 glycosylation analyzer, POCT chemiluminescence platform CF10/CP800, dozens of chemiluminescence reagents, blood gas analysis platform PT1000, and various molecular diagnostic reagents for the novel coronavirus nucleic acid test. Additionally, it has introduced comprehensive solutions for PCR laboratory construction, intelligent fever clinic development, and nucleic acid testing.